Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

54.27
+3.717.34%
Post-market: 55.421.15+2.12%19:57 EDT
Volume:5.56M
Turnover:305.32M
Market Cap:8.31B
PE:19.60
High:56.87
Open:51.10
Low:49.97
Close:50.56
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:3.94
T/O Rate:3.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.75
PE(LYR):19.59

Loading ...

Stock Track | TG Therapeutics Soars 15.91% Intraday on Raised Revenue Guidance and Strong Q1 Results

Stock Track
·
May 07

TG Therapeutics Up Over 14%, on Pace for Largest Percent Increase Since August 2024 -- Data Talk

Dow Jones
·
May 07

TG Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 07

TG Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $70 From $60

THOMSON REUTERS
·
May 06

TG Therapeutics Q1 Adj. EPS $0.18 Misses $0.30 Estimate, Sales $204.918M Beat $196.814M Estimate

Benzinga Earnings
·
May 06

TG Therapeutics Q1 revenue rises, lifts 2026 outlook

Reuters
·
May 06

Earnings Flash (TGTX) TG Therapeutics Posts Q1 EPS $0.12, vs. FactSet Est of $0.28

MT Newswires Live
·
May 06

TG Therapeutics Q1 Product Revenue USD 201.308 Million

THOMSON REUTERS
·
May 06

TG Therapeutics Q1 Net Income USD 19.777 Million

THOMSON REUTERS
·
May 06

TG Therapeutics Raises FY 2026 Total Global Revenue Target to Approximately $925 Million

THOMSON REUTERS
·
May 06

TG Therapeutics Q1 EPS USD 0.12

THOMSON REUTERS
·
May 06

Precision Bio Q1 sales beat, helped by milestone revenue

Reuters
·
May 05

TG Therapeutics Inc expected to post earnings of 30 cents a share - Earnings Preview

Reuters
·
May 04

TG Therapeutics announces annual shareholder meeting via webcast

Reuters
·
May 01

TG Therapeutics to host conference call on first-quarter results and 2026 outlook

Reuters
·
Apr 30

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

Goldman Sachs Reaffirms Their Hold Rating on TG Therapeutics (TGTX)

TIPRANKS
·
Apr 16

TG Therapeutics completes enrollment in Phase 3 subcutaneous Briumvi trial in MS

Reuters
·
Apr 15

TG Therapeutics Inc - Top-Line Data From Phase 3 Subcutaneous Briumvi Trial Expected Year-End 2026 or Q1 2027

THOMSON REUTERS
·
Apr 15

Analysts Conflicted on These Healthcare Names: TG Therapeutics (TGTX), Insmed (INSM) and Solventum Corporation (SOLV)

TIPRANKS
·
Apr 08